-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, D9aV8R1STJKl5VzMNPtlxhT7VsXit4vC7FJvbbAxjxc8fKGvWme2+PLZHbZGJw82 5VDEkD0oSfQWj7v23baxrg== 0000950103-04-000866.txt : 20040618 0000950103-04-000866.hdr.sgml : 20040618 20040618132526 ACCESSION NUMBER: 0000950103-04-000866 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20040618 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20040618 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29630 FILM NUMBER: 04870381 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 BUSINESS PHONE: 1264333455 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 8-K 1 jun1804_8k.htm 06.18.04.8K

UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 18, 2004

 

               Shire Pharmaceuticals Group plc               
 (Exact name of registrant as specified in its charter)

                           England and Wales                           
(State or other jurisdiction of incorporation)

0-29630
(Commission File Number) 		98-0359573
(IRS Employer Identification No.)

 

Hampshire International Business Park, Chineham, Basingstoke,
                           Hampshire RG24 8EP England                           
(Address of principal executive offices)    (Zip code)

Registrant's telephone number, including area code         44 1256 894 000

________________________________________________________________________________
(Former name or former address, if changed since last report)





Item 5. Other Events

     Shire Pharmaceuticals Group plc has issued the press releases attached as Exhibit 99.1 and Exhibit 99.2 and which are incorporated by reference herein.

Item 7. Financial Statements and Exhibits

          (c) Exhibits. The following exhibits are filed herewith:

99.1      Press Release dated June 18, 2004
99.2      Press Release dated June 18, 2004
   





SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  SHIRE PHARMACEUTICALS GROUP PLC
     
  By:

/s/ A C Russell                

   
    Name:  Angus Russell
    Title:    Chief Financial Officer

Dated: June 18, 2004





EXHIBIT INDEX

Number
 Description
 
99.1     
Press Release dated June 18, 2004
99.2     
Press Release dated June 18, 2004

 





 EX-99.1 2 jun1804_ex9901.htm Untitled Document
  EXHIBIT 99.1
   
Shire Pharmaceuticals Group plc
Hampshire International Business Park,
Chineham, Basingstoke RG24 8EP UK
Tel +44 1256 894000 Fax +44 1256 894708
http://www.shire.com
18 June 2004  

 

Shire Pharmaceuticals Group plc (the "Company")

The Company announces that it was notified on 18 June 2004 under Sections 198 to 202 of the Companies Act that FMR Corp. and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries, both being non-beneficial holders, held solely for investment purposes in aggregate 52,526,136 ordinary shares of £0.05p each in the capital of the Company. These holdings represent 10.94 per cent of the issued ordinary share capital of the Company.

T May 
Company Secretary 

 

For further information please contact:

Investor Relations  
   
Cléa Rosenfeld +44 1256 894 160

 

Notes to editors

Shire Pharmaceuticals Group plc

Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world's key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.

For further information on Shire, please visit the Company's website: www.shire.com



 GRAPHIC 3 shire.gif GRAPHIC begin 644 shire.gif M1TE&.#EA2`&*`/<```0N:00N<`\N80\N<`\N=P\N?P\W80\W:0\W<`\W=P]` M=P]`AAHN6AHN81HN^\3"R,3"S\3"Y<3,S\3,Y<3,],35[<35],3>^\_,S\_,U\_, MY<_,],_5S\_5U\_5WL_5[<_5],_>[<_>],_H[<_H^]K5U]K5WMK5Y=K5]-K> MWMK>Y=K>^]KHY=KH^]KQ^^3>WN3>Y>3>[>3>].3HWN3HY>3H[>3H].3Q^^3Z M^^_H]._Q[>_Q^^_Z^_KH]/KQ]/KQ^_KZ[?KZ^P`````````````````````` M```````````````````````````````````````````````````````````` M`````````````````/___R'Y!`$``/\`+`````!(`8H`0`C_`/\)'$BPH,&# M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRIA4X#*:SE(M!2F49\ZQ:-,FG,8+VT@>-"XZO8F0FK*?:O/JW;OTEX<[ M_XC1H'$B+D>Z?!,K7DQQIC"\`FT5?5A,D"!5@=?P>!;JQ!>-3B$S'DV:<;-F M!ITM/8/%X,4Q"Q6@^Q,66F.J_9T<>&BA8TA76P(<,"`08@5 M2ZY86>*!@8K?V`\6]?FOJT4L-*K4_[#T[T@*@KW$0KPK\''VA<8^-#_S+\X$ M`0R8##.(2("``00$$````_BG14*'_"?@@`(8HM$MK;#2RH2L8/;>1S+U,ME! MRTBDA@=LS,%`(;7L<*%$NFC``!P)$<+````4,&``"0Q((($#!#``C`ZTL(=# MAS20(XP``"`!``)`X-]_`E0@8)$["F`,0HX(4"0`##)`"D)68DE``0`H4&0" M!!(PP`,"7%!0-`TH6*1_+60RY3"B,``!E@$0($`#3?`53&L3W;`(+EF`L((> M`CD2"FW880)"0XX9"0'54FD@`(4@I`D M`M@8)8L'L?^*)8[^K<+EC5`*``)#QS#0I8`$0-#"L"OX,"RQQR)[@QJ+H3:0 M=QC1\($86?QCR0F4\"7*"B_V*`I#U4CUCQ;^%3D@`C,^B>.817(@0`VY)62( MG4L6B.A!FUAYP)4-<%JJKT0B*<"6!_T'XP'^0?`!1$WX:N67-IJK+IRVGJA, M,LX.]!5W)W;L\<<8N2>,,""7;/+)#>V&\LHLM^SRRS"#[%;,--=L\\TXYZSS MSCSW[/-2P53S#S4)!$@0I40,*2:AW$4_0_N-,T6CG_1+&"2G_8XN&$7G` MPS]X,!`&,2=8:)$R2_\4C&\"!9.QWI0G53=$@O"0@@=+)"2*(A,=]<]3`IE= M^>DN$4T0U!O5`$*\&#F3C$T#S=3,AB>7\5^`.@J@`1^).#%@D`D!)24)` M!I7^9R,?(&0/=P(`N@I4ABDN*$`%*@67``BC*+6`(37X'P`F,(*$H(**.F)` M+OR4DVK8<705L4/BGH&%#RPB$\P:C1ZL%(`I1&0,`+O1C@I$!C$*I('&&$+` MT'4C`00!(0F26`!2A9!,M,I8I5U.ITB%R"]2D((O5((''H#A1&GAFVK0 M0JI)1=U%/0*;#_3I'S087$5"8Q2?/"V:64TK09RA""8DX0K$(%DE/$`#,"!! M#A5IAC1[XQ/VJ-6;C(L:WA8""@:L814\.`$6:G.#*U"0*^^LZ4R6^5=B*L-9 M_W?["B_(UI`P>&`5;A/%(`J*$8V.[BB\H&QEF^FWD3W-(X.03]:X(JZKKO:: MSJ#%,G;;3HJ`0@8,L%`H7&<"\EGDM5YYZ&V9V1N-+H.J?I5((*J2B7]@X38? M^``>F*&1912E?2R+@G\&``$EU0\`$-B`?Q"F)%$6!`:?((@C'I7$!H`.(XIH MCG^:TYS'ULQ9^/S.9_XA"`]X8!$"J00-&*`$B>BUN8(UG<=4<8'Z'4`(LG"% M"QB`@?$.``$!$Y`%](0!*PY$&$@3R"$<0*0M2@\CIDH7`@S@R)Z);G2,"KF$#^#7)OZ>H!&,B0KC`DQ8P>7&$AZH@T!JP5V89:(Y'C!%07[` M8@`D@$Q7@L``VM0`#&1A?Q))4([410(EB9IX6")3@03@WX%426($:D"-"R(` M=.7)B0.8@@L<0`#>$4B5!"'&"I8$``(DP(DT4N$2_?.!*:&E&0%M)TVLRHN1 M+N0+,K##%4Y@B3;DYV2C*,6CG-`01`J@V#8*@"L-F``%,`@!][FD0C+Y)#() M0`12),@FA!2P`I&J5/\#HP#_=DT04N9)``=`6`;\0)!G*.X?QK"@"I$$:(/8 M*4`R8F1>."J5WGA4(J&`C2,$@HL/H,`R'K@X:3"Q)%&`0B.Y.(00D+B<,CI1 MBW":XJK]?2^#J#J!P,;#%&=5QH'=ZDIDBD`#&!(-7WF:Z6:&.-`1=C_B%:C+ M>J'&4#3F%9MX&R'#L,+5/+"&?ZSA`U>+P(ANO#5`XBGP1\IY`)9 MM-&S!2#G@JCZ2IM45:SPE"OW$D16HE)@Q0S2JAT!4%<-:<(G:P0`9-LSV]W1 M$)(=D@0:/.,76#`PH_0"Y00\02)OJ/"5$)#`""RI7J!Z4BD98.*#-.]4B4<( MS76_N$G'V]KA;V+X0!R>RH>`(&#-1A(#1.""$:AW`!LO4,=_,Y.RUA1FAG@4 M$OG;G!VH06X(>4,#(+C(=2$I2@U@P%<9HC9?V9\!+S8()<9/_J(79*[DQU^7 MN%%K M910?.((7P1JVU4YBDV,DN(()47)?D8$L&(,R.(,@\3@T>(,XF(,ZN(,\V(,^ M^(-`&(1".(3_1%B$1GB$2)B$2KB$3-B$3OB$HT$-P7!,2.-.9Z<2LY,:,%@R M1",5-OB#?B5A$M$+'I`M(!$5))-;+",31L$+8JB#'!,5&!$(Z,<1%'43*;8R M=R,5RM!1;TB#88,88C<+T:438@-#J04X+`,Y36,W/XB'[01Z$T$).9"'!B%, M%*%0#?5])L,]2:.",P@YU?!<6]@0SF`%"<&`*0`"5U`,$*$Z`H%5*T,-5WB# M3F&)'#$,/H`"*<`(`E$%Z1,1=G$42&-,9M$RD@B%#4$)1>`!)_`+8'4",^`# MU1%?%$$-MH`7M'`[M:B,.V-Q4*,*OK`XR^!.WO@Q$<41SY`$*``7_VH`BA-! M#Y:P`C^`"ZG7$;2P67XDP61%0+!`RA@"<10 M:1;Q%<_R4;R0CD"Y%\NP61JC6@LQ5RB``@Q076O@`3/@`2:25U^8-&,WE8N! M#71S-^!S5`\A"#2P"`R`8%=C#;_"(EFG1-"+Y$*I``ZN0!_+GB!L1+APC M%'I)&GO8EPR1!HKE4PJ)F),1=>41'#P`!7PP>E\`$>8`RE4`,I@(FT]1.KX0Q$Q9IJ MX1UTD9<'(0A&)A!Y(!N#X(H6`1DW)IQZ,1.-R(C@11%7L%*1H0:"4)EY!7KA MFQ3.M``EN0&48X4@01T\`]RF0*#\`^,P`#DL3BQ M"!:*N#+%,$(.4R`(4&8#@$$#``6[0(!7T#D%,0RK]P\3>A'6A@S1D*$5BC.P M:)P(D03?@@4GP`:P,1">$`-H%E,_$9TK(P7ULR/O-P!40`0E,`%(8@`%@C`K M8&VK@P;R%4$[HB?__E<1CT!P48(?,E`"!F,F!A0J`/```P`"A2<0]R40_?$F M6"(`0TH1U(,G"K<):`.=%W$+D\D#)ZD12"&5V(%(;>("J+`+9U`_EXI@&-30I7B1 M6\99"2?@C(Z@"A(:EC)0G_\P\PPW`"D$46$;`*.>9F;RMPC].!'[^B0"4`9< MX"MC*C#F8F9BX$!*!$`-4&O_T"HZ0B0#4`:Q4$M70@!M9!#"0&:GPGFQ]B8: ML`(;JA1,JAHUQ5&=>1!8`Z&:<`)?PS*7QGOO67$,L+/F\CPW4CU'HD$UL`B3 MUQ!#:R-FLD@\.RNTLGT%<6MX,B!:,D9-Q*X<`*,"(FLA5!!;(``8Y'[[52ZK MAEX,L`*)<55'\:4&H08P]0@@D%TKAS*:P``7(`G2:A"#A$&H]+@+\D'HA1^* MY[1#ARLN``>M$`V:0`8>%``)]":ML'2[BQ\$0WF:1`&M@@"WUP#,X0$%00;$ M2@'_2A(I!1$)OK*[;WJP:@&<;:L0JI`$*_4!BD>-"^:=%W)I_I$!M9L0>O`! M[)<`R7HEOY(`1X(?*P"9")P)@`/N5KWL!G"%I%*AK M$+=`"3YE".C#"*NP8(K!"@Y3F@M!"@6Z2/C!$!C@`*@TL`-0:YDD,8U<$*SB M*J&T*H1420(PN`U7M;E2P@?!`-532EW;,A(I$(S9$#1@!/_P!3^0!#,P=WK1 M"DD2`2[P#]?@?)P+(PD$(Q!PR M%&_-['O(AR273+7#O-`&00AN*\4(Y]#^H<(`^L`9K@!DY*0RIT`B! M0`E2I06=!B6K!FU0`F*]NT$,4;=[4FC+.A"5D$3[%4@&X0BPO5\F_0^U'7_: M"Q%W<`%:BWV:+#`-D`%ED,@?XQ0U%:`1T0<>$`B+@0RE(`JD@`MBK1"K```$0S`$3O`'I&#>(#.%&I.9 MTEE-?4A43M'-]VU-VP8YLMC?PP2<=A/@`LY,L`@51R$V,G3@T\11#[FB!N[@ I>J,T0P/2%)[A&K[A6=4+% EX-99.2 4 jun1804_ex9902.htm Untitled Document
  EXHIBIT 99.2
   
Shire Pharmaceuticals Group plc
Hampshire International Business Park,
Chineham, Basingstoke RG24 8EP UK
Tel +44 1256 894000 Fax +44 1256 894708
http://www.shire.com
18 June 2004  

 

Shire Pharmaceuticals Group plc (the "Company")

The Company announces that documents detailing resolutions, other than resolutions concerning ordinary business, which were passed at its Annual General Meeting on 16 June 2004, have been submitted to the UK Listing Authority, and will shortly be available for inspection at the UK Listing Authority's Document Viewing Facility, which is situated at:

Financial Services Authority
25 The North Colonnade
Canary Wharf
London
E14 5HS
Tel No. (0)20 7676 1000

T May
Company Secretary

For further information please contact:

Investor Relations  
   
Cléa Rosenfeld +44 1256 894 160

Notes to editors

Shire Pharmaceuticals Group plc

Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world's key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.

For further information on Shire, please visit the Company's website: www.shire.com



 -----END PRIVACY-ENHANCED MESSAGE-----